Completed PHASE2 INTERVENTIONAL 2-arm NCT01684761

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (Abili-T)

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

Sponsor: Opexa Therapeutics, Inc.

Conditions Autoimmune Diseases of the Nervous System Brain Atrophy Disease Progression Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Interventions Placebo Tcelna

Updated 6 times since 2017 Last updated: Jan 9, 2017 Started: Aug 31, 2012 Primary completion: Oct 31, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Autoimmune Diseases of the Nervous System and Brain Atrophy and is currently completed. Opexa Therapeutics, Inc. leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Opexa Therapeutics, Inc.

Data source: Opexa Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Berkeley, United States , Boston, United States , Burlington, United States , Charlotte, United States , Dayton, United States , Fort Wayne, United States , Greenfield Park, Canada , Houston, United States , Indianapolis, United States and 24 more locations